The internal review boards and ethics committees of all collaborating hospitals

in the surveillance network approved the protocol, and written informed consent was collected from the MM-102 supplier guardians of all participants to obtain fecal and/or blood samples, and {Selleck Anti-cancer Compound Library|Selleck Anticancer Compound Library|Selleck Anti-cancer Compound Library|Selleck Anticancer Compound Library|Selleckchem Anti-cancer Compound Library|Selleckchem Anticancer Compound Library|Selleckchem Anti-cancer Compound Library|Selleckchem Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|Anti-cancer Compound Library|Anticancer Compound Library|buy Anti-cancer Compound Library|Anti-cancer Compound Library ic50|Anti-cancer Compound Library price|Anti-cancer Compound Library cost|Anti-cancer Compound Library solubility dmso|Anti-cancer Compound Library purchase|Anti-cancer Compound Library manufacturer|Anti-cancer Compound Library research buy|Anti-cancer Compound Library order|Anti-cancer Compound Library mouse|Anti-cancer Compound Library chemical structure|Anti-cancer Compound Library mw|Anti-cancer Compound Library molecular weight|Anti-cancer Compound Library datasheet|Anti-cancer Compound Library supplier|Anti-cancer Compound Library in vitro|Anti-cancer Compound Library cell line|Anti-cancer Compound Library concentration|Anti-cancer Compound Library nmr|Anti-cancer Compound Library in vivo|Anti-cancer Compound Library clinical trial|Anti-cancer Compound Library cell assay|Anti-cancer Compound Library screening|Anti-cancer Compound Library high throughput|buy Anticancer Compound Library|Anticancer Compound Library ic50|Anticancer Compound Library price|Anticancer Compound Library cost|Anticancer Compound Library solubility dmso|Anticancer Compound Library purchase|Anticancer Compound Library manufacturer|Anticancer Compound Library research buy|Anticancer Compound Library order|Anticancer Compound Library chemical structure|Anticancer Compound Library datasheet|Anticancer Compound Library supplier|Anticancer Compound Library in vitro|Anticancer Compound Library cell line|Anticancer Compound Library concentration|Anticancer Compound Library clinical trial|Anticancer Compound Library cell assay|Anticancer Compound Library screening|Anticancer Compound Library high throughput|Anti-cancer Compound high throughput screening| use the clinical and microbiologic information for scientific studies [1]. The ST213 strain YU39 was used as a pA/C donor, since this was the only strain capable of conjugal transfer [5]. This strain harbored five plasmids: the 150 kb pA/C and four plasmids of different sizes (ca. 100, 40, 5 and 3 kb), for which no information was available. We selected strain SOHS 02-2 (hereafter referred to as SO1) which contains a 94 kb pSTV and a cryptic 80 kb plasmid [4], and the reference strain LT2 which only carries the 94 kb pSTV [8], as representative strains of the ST19 genotype harboring pSTV. The pSTV of SO1 and LT2 were marked with a kanamycin resistance cassette inserted into the spvC gene (coding for a phosphothreonine lyase) according to the Datsenko and Wanner protocol [9]. These strains were named SO1pSTV::Km

and LT2pSTV::Km, and were used as recipients in conjugation experiments (Table 1). Table 1 Bacterial strains and plasmids used in this work Strain Plasmids (kb) Feature Salmonella     YU39 (ST213) pA/C (150), p100 (100), pX1 Torin 2 (40), pColE1-like (5), p3 (3) Donor SO1 (ST19) pSTV::Km (94), p80 (80) Recipient LT2 (ST19) pSTV::Km (94) Recipient E. coli     DH5α   Recipient HB101   Recipient HB101pSTV pSTV::Km Rebamipide Recipient DH5α pA/C Wild-type pA/C, donor DH5α pA/C, pSTV::Km Stability assays DH5α pX1 Wild-type pX1 Transconjugants     SO1     IA4 pA/C Re-arranged pA/C IA5 pA/C Re-arranged pA/C IA9 pA/C Re-arranged pA/C IIA4 pA/C + pX1 pA/C and pX1 co-integrate HB101     IC2 pX1::CMY pX1 with

the transposed CMY region IIC1 pX1::CMY pX1 with the transposed CMY region IIIC9 pA/C + pX1 pA/C and pX1 co-integrate IIIC10 pX1::CMY pX1 with the transposed CMY region IVC8 pA/C + pX1 pA/C and pX1 co-integrate HB101pSTV ::Km     ID1 pX1::CMY pX1 with the transposed CMY region IID2 pX1::CMY pX1 with the transposed CMY region IIID8 pA/C + pX1 pA/C and pX1 co-integrate IVD2 pA/C + pX1 pA/C and pX1 co-integrate IVD8 pX1::CMY pX1 with the transposed CMY region LT2     IIE2 pX1::CMY pX1 with the transposed CMY region IIIE4 pX1::CMY pX1 with the transposed CMY region IIIE9 pA/C + pX1 pA/C and pX1 co-integrate DH5α     221-1 pA/C + pX1 pA/C and pX1 co-integrate 221-10 pA/C + pX1 pA/C and pX1 co-integrate 225-1 pA/C + pX1 pA/C and pX1 co-integrate 225-7 pA/C + pX1 pA/C and pX1 co-integrate pX1 mutants     DH5α pX1ydgA::Tn5 Tn5 transposon insertion DH5α pX1taxB::Km taxB site-directed mutant DH5α pA/C, pX1ydgA::Tn5 Donor DH5α pA/C,pX1taxB::Km Donor Transformation of pA/C and pSTV into E.